{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2007"],"condition":["Colorectal Neoplasms","Colorectal, Cancer"],"disease":["Colorectal Neoplasms","Colorectal, Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2047203"],"location":["Japan"],"study_start_month":["10"],"keyword":["Irinotecan","S-1, Bevacizumab, Irinotecan","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer","description":"Phase II trial of combination therapy with S-1, irinotecan, and bevacizumab (SIRB) in patients with unresectable or recurrent colorectal cancer","dates":{"creation":"2007-10-15"},"accession":"2047203","cross_references":{"ClinicalTrials___gov":["NCT00569335"]}}